Firm at a glance
Deerfield is a platform private equity firm founded in 1994 and headquartered in New York, NY, per its own website [S1]. The firm reports approximately $16 billion in assets under management as of December 2025 [S1] and maintains offices in New York and Doha [S2].
What they buy
Deerfield’s portfolio demonstrates a consistent focus on healthcare investments across three observable segments: healthcare services, medical technologies, and therapeutics [S3]. The firm’s portfolio companies span data analytics and care delivery platforms, medical device manufacturers, and drug development ventures. Recent acquisitions between 2024 and 2025 include healthcare services businesses, medical technology companies, and therapeutics platforms, suggesting active deployment across all three healthcare subsectors [S3].
Portfolio
Healthcare Services
Verana Health (acquired October 2022), Excelsior Sciences (acquired January 2024), Ascertain (acquired April 2025), Vanova Health (acquired May 2024), Pipeline Health (acquired January 2019), Lumeris (acquired April 2016), Neuroflow, Blink Health (acquired March 2019), and Concert (acquired December 2017) [S3].
Medical Technologies
Alpfa Medical (acquired December 2024), Atlas Data Storage (acquired May 2025), and Conventus Flower Orthopedics (acquired November 2014) [S3].
Therapeutics
Bluefin Biomedicine (acquired July 2025), Sequel Therapeutics (acquired November 2018), and Parabilis Medicines (acquired October 2016) [S3].
Recent activity (last 24 months)
* Bluefin Biomedicine acquisition, July 2025 [S3]
* Atlas Data Storage acquisition, May 2025 [S3]
* Ascertain acquisition, April 2025 [S3]
* Nuvalent, Inc. exit, 2025 [S2]
* Alpfa Medical acquisition, December 2024 [S3]
* Vanova Health acquisition, May 2024 [S3]
* Excelsior Sciences acquisition, January 2024 [S3]
How this firm fits a seller
Deerfield appears suited for healthcare businesses seeking a buyer with sector depth and a multi-decade track record in the space. The firm’s transaction history shows activity across early-stage therapeutics companies and more established healthcare services platforms, suggesting flexibility in deal size and company maturity. The 2025 exit of Nuvalent indicates the firm maintains an active portfolio management approach [S2]. For sellers in healthcare services, medical devices, or life sciences, Deerfield’s observed pattern of sustained sector commitment may offer continuity for specialized management teams.
Sources
[S1] https://deerfield.com/about (as of 2025-12-01)
[S2] https://deerfield.com/about/news (as of 2025-12-01)
[S3] https://deerfield.com/what-we-do/investment/portfolio (as of 2025-12-01)
Frequently asked questions
Does Deerfield buy Healthcare Services businesses?
Yes, healthcare services represents the largest observable segment in Deerfield’s portfolio, with at least nine companies in this category per public sources [S3]. Recent acquisitions include Ascertain in April 2025 and Vanova Health in May 2024 [S3].
What companies has Deerfield acquired recently?
Deerfield’s most recent acquisitions include Bluefin Biomedicine in July 2025, Atlas Data Storage in May 2025, and Ascertain in April 2025 [S3]. The firm also acquired Alpfa Medical in December 2024 [S3].
Where is Deerfield based and how big is the firm?
Deerfield is headquartered in New York, NY, with an additional office in Doha [S1][S2]. The firm reports approximately $16 billion in assets under management as of December 2025 [S1].
Is Deerfield still actively acquiring?
Yes, Deerfield completed at least six acquisitions between January 2024 and July 2025, indicating active deal activity [S3]. The firm also executed an exit of Nuvalent, Inc. in 2025 [S2].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.